{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:45:39Z","timestamp":1785905139278,"version":"3.56.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Although both metabolic syndrome (MetS) and irritable bowel syndrome (IBS) have been linked with altered gut microbiota, only a few studies investigated the association between them. Hence, we aimed to evaluate the prevalence of MetS along with depression and fibromyalgia syndrome (FMS) in IBS patients.<\/jats:p>\n            <jats:p>This was a case-control study in which 3808 consecutive patients who attended outpatient clinics of Erzurum Regional Training and Research Hospital between May 2019 and August 2019 were evaluated in terms of IBS with Rome-IV criteria. Out of 486 patients who were diagnosed as IBS, 176 patients were excluded for various reasons. Control subjects were randomly selected from IBS-negative subjects. MetS was diagnosed based on International Diabetes Federation criteria. Depression, anxiety disorder, and FMS were assessed via Hamilton Depression Scale, Beck Anxiety Inventory, and American College of Rheumatology criteria, respectively. Blood samples were obtained to measure biochemical parameters.<\/jats:p>\n            <jats:p>Study group included 310 IBS patients, and control group included 304 subjects. The prevalence of the MetS was significantly higher among IBS patients compared with controls (36.8% vs 21.7%, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.006). The rate of obesity was 18.1% among IBS subjects, and 10.2% in the controls. The prevalence of fibromyalgia (30% vs 3%, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001), anxiety-disorder (39.7% vs 10.2%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) and depression (8.1% vs 4.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) were significantly higher in IBS group than controls.<\/jats:p>\n            <jats:p>Metabolic syndrome and obesity were significantly more frequent in IBS patients compared with controls. FMS, anxiety disorder, and depression were also more common among IBS patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020577","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:02:00Z","timestamp":1591214520000},"page":"e20577","source":"Crossref","is-referenced-by-count":21,"title":["Metabolic syndrome, depression, and fibromyalgia syndrome prevalence in patients with irritable bowel syndrome"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-4181","authenticated-orcid":false,"given":"Muharrem","family":"Bayrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","article-title":"The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome","volume":"57","author":"Pyleris","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"8709","DOI":"10.3748\/wjg.v20.i26.8709","article-title":"I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life","volume":"20","author":"Lorenzo-Zuniga","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ajg.2011.355","article-title":"The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis","volume":"107","author":"Menees","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1074248416686187","article-title":"Metabolic Syndrome","volume":"22","author":"Sherling","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen","year":"2018","journal-title":"Curr Hypertens Rep"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2013.09.009","article-title":"Metabolic syndrome","volume":"43","author":"Samson","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"(2 Suppl 1)","key":"R9-20230915","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.dsx.2016.01.024","article-title":"Gut microbiome and metabolic syndrome","volume":"10","author":"Mazidi","year":"2016","journal-title":"Diabetes Metab Syndr"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"e112289","DOI":"10.1371\/journal.pone.0112289","article-title":"Irritable bowel syndrome is positively related to metabolic syndrome: a population-based cross-sectional study","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3349\/ymj.2016.57.1.146","article-title":"Irritable bowel syndrome may be associated with elevated alanine aminotransferase and metabolic syndrome","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Med J"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","article-title":"A structured interview guide for the Hamilton Depression Rating Scale","volume":"45","author":"Williams","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R15-20230915","first-page":"411","article-title":"Obesity and irritable bowel syndrome: a comprehensive review","volume":"10","author":"Pickett-Blakely","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s42000-019-00113-9","article-title":"Irritable bowel syndrome: a new therapeutic target when treating obesity?","volume":"18","author":"Pugliese","year":"2019","journal-title":"Hormones (Athens)"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cyto.2011.11.019","article-title":"Cytokines and irritable bowel syndrome: where do we stand?","volume":"57","author":"Bashashati","year":"2012","journal-title":"Cytokine"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ajg.2014.422","article-title":"Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome","volume":"110","author":"Lee","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"324","DOI":"10.5056\/jnm.2012.18.3.324","article-title":"Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center","volume":"18","author":"Singh","year":"2012","journal-title":"J Neurogastroenterol Motil"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2011.01.032","article-title":"The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome","volume":"140","author":"Chang","year":"2011","journal-title":"Gastroenterology"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature11552","article-title":"Functional interactions between the gut microbiota and host metabolism","volume":"489","author":"Tremaroli","year":"2012","journal-title":"Nature"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1038\/ctg.2015.16","article-title":"The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease","volume":"6","author":"Parekh","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"issue":"(Pt 11)","key":"R23-20230915","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1099\/mic.0.043257-0","article-title":"Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives","volume":"156","author":"Salonen","year":"2010","journal-title":"Microbiology"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/gutjnl-2012-302167","article-title":"Intestinal microbiota in functional bowel disorders: a Rome foundation report","volume":"62","author":"Simren","year":"2013","journal-title":"Gut"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1017\/S0033291716001987","article-title":"A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset","volume":"46","author":"Sibelli","year":"2016","journal-title":"Psychol Med"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"e6657","DOI":"10.1097\/MD.0000000000006657","article-title":"Risk for irritable bowel syndrome in fibromyalgia patients: a national database study","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.3748\/wjg.v20.i20.6024","article-title":"Irritable bowel syndrome: relations with functional, mental, and somatoform disorders","volume":"20","author":"Hausteiner-Wiehle","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:05:28Z","timestamp":1694822728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020577"}},"subtitle":["A case-control study"],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":27,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020577","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}